Roche’s Xolair Gains FDA Approval to Combat IgE-Mediated Food Allergies in Patients Aged 1 and Up
Roche (SWX: ROG) has announced that the U.S. Food and Drug Administration (FDA) has granted...
SWX: ROG
Roche’s Piasky (Crovalimab) Secures NMPA Approval for Untreated Paroxysmal Nocturnal Hemoglobinuria
The National Medical Products Administration (NMPA) has granted marketing approval to Swiss pharmaceutical giant Roche...
Roche Secures NMPA Approval for Rozlytrek to Treat Pediatric NTRK Fusion-Positive Tumors
Swiss pharmaceutical giant Roche (SWX: ROG) has received a new indication approval from the National...
Roche’s Faricimab Shows Sustained Vision Benefits in Phase III Study for Retinal Vein Occlusion
Swiss pharmaceutical giant Roche (SWX: ROG) has released interim Phase III data for its bispecific...
Roche Posts Modest 2023 Growth Amid Shifts in Demand for COVID-Related Products
Swiss pharmaceutical giant Roche (SWX: ROG) has published its 2023 financial results, showing a modest...
Roche’s Tecentriq in Combination with Exelixis’s Cabometyx Meets Primary Endpoint in mCRPC Phase III Study
Roche (SWX: ROG), the Swiss pharmaceutical giant, has announced positive results from a Phase III...
AstraZeneca’s Imfinzi Meets Primary Endpoint in Hepatocellular Carcinoma Trial
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced the successful completion of the primary endpoint...
Roche’s Tecentriq SC Receives European Nod as First Subcutaneous PD-(L)1 Therapy
Halozyme Therapeutics (NASDAQ: HALO) has announced that the European Commission (EC) has granted marketing authorization...
C4 Therapeutics Outlines 2024 Focus Amid 30% Workforce Reduction, Prioritizes Key Oncology Trials
C4 Therapeutics (NASDAQ: CCCC), a leader in protein degradation, announced this week its strategic focus...
Merck In-Licenses Inspirna’s Ompenaclid for Advanced Colorectal Cancer, Eyes Market Potential
Germany-based Merck (NYSE: MRK) has in-licensed the potential first-in-class candidate ompenaclid from U.S. firm Inspirna,...
Roche’s Phesgo and Faricimab Receive NMPA Approvals for Breast Cancer and nAM
The National Medical Products Administration (NMPA) has granted separate approvals for two distinct drugs from...
Roche to Expand Diagnostics Portfolio with Acquisition of LumiraDx Technology
Pharmaceutical giant Roche (SWX: ROG), based in Switzerland, has announced an agreement to acquire innovative...
Roche Secures Diagnostics Deal with LumiraDx for $295M
Switzerland’s pharmaceutical giant Roche (SWX: ROG) has sealed a deal to acquire innovative diagnostics technology...
Medilink Therapeutics Secures Multi-Billion Dollar Deal with Roche for c-MET Targeting ADC
Medilink Therapeutics, a Suzhou-based biopharmaceutical company, has entered into a global collaboration and licensing agreement...
FDA Prioritizes Roche’s Xolair for Food Allergy Indication Extension Ahead of Q1 Decision
The U.S. Food and Drug Administration (FDA) has prioritized Roche’s (SWX: ROG) indication extension filing...
Roche Diagnostics and Beijing Strong Biotechnologies Deepen Ties to Innovate in Hemostasis Diagnostics
Roche Diagnostics (SWX: ROG), the Swiss diagnostics heavyweight, has furthered its collaboration with Beijing Strong...
Roche Receives NMPA Approval for Ophthalmology BsAb Vabysmo (Farcimab) for Diabetic Macular Edema
Swiss pharmaceutical giant Roche (SWX: ROG) has announced that it has obtained marketing approval from...
Bio-Thera Secures FDA Approval for Avzivi, a Biosimilar to Roche’s Avastin
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has announced that it has received market approval from the...
Roche Expands Beyond Oncology with USD 2.7 Billion Carmot Therapeutics Acquisition
Swiss pharmaceutical giant Roche (SWX: ROG) has entered into an agreement to acquire U.S. biotech...
Roche’s Mosunetuzumab and AnHeart’s Taletrectinib Poised for Priority Review in China
The China Center for Drug Evaluation (CDE) website has indicated that Roche’s (SWX: ROG) Lunsumio...